Janux Therapeutics (JANX) Operating Income (2020 - 2026)
Janux Therapeutics (JANX) posted quarterly Operating Income of -$34.2 million for Q1 2026, up 1.96% year-over-year from -$33.6 million in Q1 2025, and up 19.31% quarter-over-quarter from -$42.4 million in Q4 2025.
Janux Therapeutics (JANX) Operating Income (2020 - 2026) Analysis & Trends
Janux Therapeutics (JANX) has reported Operating Income for 7 consecutive years, with -$34.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Income rose 1.96% year-over-year to -$34.2 million; the TTM figure through Mar 2026 stood at -$157.0 million (down 38.21% YoY), while the FY2025 annual figure was -$157.7 million, down 59.51% from the prior year.
- Operating Income improved to -$34.2 million in Q1 2026 per JANX's latest filing, from -$42.4 million in the prior quarter.
- Across five years, Operating Income topped out at -$13.5 million in Q1 2022 and bottomed at -$45.1 million in Q2 2025.
- Historically, Operating Income has averaged -$25.3 million across 5 years, with a median of -$20.3 million in 2023.
- Annual changes were most pronounced in 2022 — Operating Income tumbled 492.91% — and 2024, when it jumped 33.38%.
- Janux Therapeutics' Operating Income stood at -$18.3 million in 2022, then gained by 11.66% to -$16.1 million in 2023, then slumped by 79.85% to -$29.0 million in 2024, then sank by 46.1% to -$42.4 million in 2025, then increased by 19.31% to -$34.2 million in 2026.
- Business Quant data shows JANX's Operating Income at -$34.2 million in Q1 2026, -$42.4 million in Q4 2025, and -$35.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Janux Therapeutics | 984.58 Mn | 984.58 Mn | - | -31.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -31.69 Mn |
| Mar 31, 2026 | -34.21 Mn |
| Dec 31, 2025 | -42.40 Mn |
| Sep 30, 2025 | -35.25 Mn |
| Jun 30, 2025 | -45.12 Mn |
| Mar 31, 2025 | -34.90 Mn |
| Dec 31, 2024 | -29.02 Mn |
| Sep 30, 2024 | -35.84 Mn |
| Jun 30, 2024 | -13.82 Mn |
| Mar 31, 2024 | -20.16 Mn |
| Dec 31, 2023 | -16.14 Mn |
| Sep 30, 2023 | -15.81 Mn |
| Jun 30, 2023 | -20.75 Mn |
| Mar 31, 2023 | -20.28 Mn |
| Dec 31, 2022 | -18.27 Mn |
| Sep 30, 2022 | -18.02 Mn |
| Jun 30, 2022 | -17.26 Mn |
| Mar 31, 2022 | -13.54 Mn |
| Dec 31, 2021 | -13.49 Mn |
| Sep 30, 2021 | -10.90 Mn |